Accessibility Menu
Anebulo Pharmaceuticals logo

Anebulo Pharmaceuticals(OTC) ANEB

Market Cap$13.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-95%
5 Year-95%
1 Year-89%
1 Month-16%
$0.32
-3.03%
-0.01Today
Anebulo Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.322026-08-03
Anebulo Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.03%USD 0.332026-07-27
1 month-15.79%USD 0.382026-07-02
3 month-30.43%USD 0.462026-05-05
Year to date-68.32%USD 1.012025-12-31
1 year-88.77%USD 2.852025-08-01
3 year-88.06%USD 2.682023-08-04
5 year-95.35%USD 6.882021-08-04
Since inception-95.49%USD 7.102021-05-07

Anebulo Pharmaceuticals Financials at a Glance

Market Cap

$13.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.98M

EPS (TTM)

-$0.19

P/E Ratio

-1.65

Dividend

$0.00

Beta (Volatility)

-19.77 (Low)

Price

$0.32

Volume

102

Open

$0.32

Previous Close

$0.32

Daily Range

$0.32 - $0.32

52-Week Range

$0.00 - $2.90

Estimated Earnings Date

Sep 23, 2026

ANEB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anebulo Pharmaceuticals

Anebulo develops medicines for people affected by cannabis overdose and substance addiction. Its main drug candidate aims to help adults and children recover from severe cannabis effects. The company focuses on unmet medical needs where no approved treatments exist.

What’s Cooking in the Lab?

  • Selonabant (oral): Designed for adults with acute cannabis intoxication; no revenue generated.
  • Selonabant (IV): Developed for children with cannabis-induced central nervous system depression; no revenue generated.
  • Pipeline focus: All efforts target cannabinoid intoxication and overdose; no other products in development.
  • Licensing: Holds exclusive global rights to selonabant; covers both oral and IV forms.

Growth Spurts and Strategic Moves

  • Completed Phase 2 trial for oral selonabant in adults in 2023.
  • Shifted focus to IV selonabant for children after FDA feedback in 2024.
  • Awarded a grant of up to $1.9 million from the National Institute on Drug Abuse in 2024.
  • Raised $15 million in a private placement in December 2024.
  • Plans Phase 1 study of IV selonabant in adults, pending FDA clearance in 2025.

Why Anebulo Stands Out (Without the Lab Coat)

Anebulo targets a medical problem with no approved treatments: cannabis overdose. Its exclusive rights to selonabant and focus on both adult and pediatric needs set it apart. The company’s small size allows for quick strategic shifts in response to regulatory feedback.

Five Things You Need to Know

  • No revenue reported for QQ1 2026, QQ1 2025, or QQ1 2024.
  • Net loss was $2 million in QQ1 2026, up 6.3% from QQ1 2025.
  • Cash and equivalents reached $13.3 million as of March 31, 2025.
  • Operating cash outflow improved 24.7% to $-1 million in QQ1 2026.
  • Market cap was $19.51 million with a stock price range of $0.43–$3.42.

Bottom Line

Anebulo is a focused biotech working to address cannabis overdose with a single drug candidate. The company remains pre-revenue and relies on grants and fundraising to support its research.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3

CEO

Richard Anthony Cunningham

Website

www.anebulo.com

Headquarters

Lakeway, TX 78734, US

ANEB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-74.58%

Return on Capital

-79.12%

Return on Assets

-84.68%

Earnings Yield

-60.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.78M

Volume

102

Avg. Volume

2.32K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$9.10M

EBITDA

-$7.42M

Operating Cash Flow

-$5.84M

Capital Expenditure

$0.00

Free Cash Flow

-$5.84M

Cash & ST Invst.

$9.04M

Total Debt

$0.00

Anebulo Pharmaceuticals Performance Analysis

Anebulo Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
Anebulo Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-03-31N/A
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Anebulo Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.29N/A
20232023-06-30USD -0.4760.0%
20242024-06-30USD -0.32-32.1%
20252025-06-30USD -0.25-21.0%
Anebulo Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-03-3132.0%
Q42025-06-3014.6%
Q12025-09-30-0.6%
Q22025-12-317.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$13.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.35M

N/A

Employees

3

N/A

Net Income

-$2.00M

+18.8%

EBITDA

-$1.98M

+17.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.04M

-39.7%

Total Debt

$0.00

N/A

Accounts Receivable

$56.78K

+84.6%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-84.68%

N/A

Return on Invested Capital

-1.03%

N/A

Free Cash Flow

-$1.31M

+6.6%

Operating Cash Flow

-$1.31M

+6.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ESLAEstrella Immunopharma, Inc.
$0.70-1.92%
CLNNClene Inc.
$5.19+3.49%
TLSATiziana Life Sciences Ltd
$0.97-5.89%
OKYOOKYO Pharma Limited
$1.67-0.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
PLTRPalantir Technologies
$125.65+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.96+0.05%

Questions About ANEB

What is the current price of Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals is trading at $0.32 per share.

What is the 52-week range for Anebulo Pharmaceuticals?

Over the past 52 weeks, Anebulo Pharmaceuticals has traded between $0.00 and $2.90.

How much debt does Anebulo Pharmaceuticals have?

As of the most recent reporting period, Anebulo Pharmaceuticals reported total debt of $0.00.

How much cash does Anebulo Pharmaceuticals have on hand?

Anebulo Pharmaceuticals reported $9.04M in cash and cash equivalents in its most recent financial results.

What is Anebulo Pharmaceuticals’s dividend yield?

Anebulo Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services